In a new study, the therapeutic potential of Cas9-based epigenetic gene activation is explored in mouse models of type I diabetes, acute kidney injury, and muscular dystrophy.
Check out the paper at: http://www.cell.com/cell/fulltext/S0092-8674(17)31247-3.
H.-K. Liao, F. Hatanaka, T. Araoka, P. Reddy, M.-Z. Wu, Y. Sui, T. Yamauchi, M. Sakurai, D. O'Keefe, E. Nunez, et al. (2017). In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. Cell 171.
And read more great research at http://www.cell.com/cell/home.